Biofrontera Inc Financials
This page shows Biofrontera Inc (BFRI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Biofrontera Inc has an operating margin of -27.2%, meaning the company retains $-27 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -46.1% the prior year.
Biofrontera Inc's revenue grew 11.7% year-over-year to $41.7M, a solid pace of expansion. This earns a growth score of 53/100.
Biofrontera Inc carries a low D/E ratio of 1.73, meaning only $1.73 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.
Biofrontera Inc's current ratio of 1.52 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 26/100, which could limit financial flexibility.
While Biofrontera Inc generated -$13.4M in operating cash flow, capex of $2K consumed most of it, leaving -$13.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Biofrontera Inc generates a -100.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -400.6% the prior year.
Biofrontera Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Biofrontera Inc generates $1.27 in operating cash flow (-$13.4M OCF vs -$10.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Biofrontera Inc earns $-28.4 in operating income for every $1 of interest expense (-$11.3M vs $400K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Biofrontera Inc generated $41.7M in revenue in fiscal year 2025. This represents an increase of 11.7% from the prior year.
Biofrontera Inc's EBITDA was -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.5% from the prior year.
Biofrontera Inc reported -$10.5M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.
Biofrontera Inc earned $-1.04 per diluted share (EPS) in fiscal year 2025. This represents an increase of 67.7% from the prior year.
Cash & Balance Sheet
Biofrontera Inc generated -$13.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.0% from the prior year.
Biofrontera Inc held $6.4M in cash against $0 in long-term debt as of fiscal year 2025.
Biofrontera Inc had 12M shares outstanding in fiscal year 2025. This represents an increase of 31.3% from the prior year.
Margins & Returns
Biofrontera Inc's gross margin was 75.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Biofrontera Inc's operating margin was -27.2% in fiscal year 2025, reflecting core business profitability. This is up 18.9 percentage points from the prior year.
Biofrontera Inc's net profit margin was -25.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 22.3 percentage points from the prior year.
Biofrontera Inc's ROE was -100.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 300.1 percentage points from the prior year.
Capital Allocation
Biofrontera Inc invested $3.7M in research and development in fiscal year 2025. This represents an increase of 78.0% from the prior year.
Biofrontera Inc invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 80.0% from the prior year.
BFRI Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M-22.6% | $9.0M+5.1% | $8.6M-31.6% | $12.6M+39.3% | $9.0M+15.0% | $7.8M-0.9% | $7.9M-25.3% | $10.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $854K-1.8% | $870K-27.9% | $1.2M+54.3% | $782K+16.9% | $669K+7.7% | $621K+3552.9% | $17K | N/A |
| SG&A Expenses | $10.0M-4.6% | $10.5M+21.7% | $8.7M+192.9% | -$9.3M-210.5% | $8.4M+6.4% | $7.9M-14.4% | $9.3M+1.6% | $9.1M |
| Operating Income | -$6.3M-23.6% | -$5.1M-11.7% | -$4.5M-165.6% | -$1.7M+65.5% | -$5.0M+2.2% | -$5.1M+7.2% | -$5.5M-41.4% | -$3.9M |
| Interest Expense | N/A | N/A | $120K | N/A | N/A | $620K-56.4% | $1.4M+3129.5% | $44K |
| Income Tax | $6K-71.4% | $21K+2200.0% | -$1K+50.0% | -$2K-166.7% | $3K-85.0% | $20K+1900.0% | $1K+116.7% | -$6K |
| Net Income | -$6.6M-24.9% | -$5.3M-26.7% | -$4.2M-201.1% | -$1.4M+75.4% | -$5.7M-2105.8% | -$257K+97.5% | -$10.4M-396.0% | $3.5M |
| EPS (Diluted) | $-0.62-8.8% | $-0.57-21.3% | $-0.47 | N/A | $-0.98-1860.0% | $-0.05+98.3% | $-2.88 | N/A |
BFRI Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.4M-23.5% | $20.1M+21.4% | $16.6M-24.9% | $22.1M+19.4% | $18.5M-14.2% | $21.6M-12.2% | $24.6M-12.0% | $27.9M |
| Current Assets | $14.4M-23.4% | $18.8M+22.7% | $15.3M-25.9% | $20.7M+22.3% | $16.9M-3.1% | $17.5M-13.3% | $20.2M-12.7% | $23.1M |
| Cash & Equivalents | $3.4M-52.8% | $7.2M+305.5% | $1.8M-69.8% | $5.9M+105.5% | $2.9M-34.4% | $4.4M+14.7% | $3.8M+184.2% | $1.3M |
| Inventory | $4.3M+7.5% | $4.0M-38.3% | $6.5M-1.8% | $6.6M+1.8% | $6.5M+65.4% | $3.9M-42.9% | $6.9M-36.7% | $10.9M |
| Accounts Receivable | $3.0M-24.3% | $4.0M-1.9% | $4.0M-24.2% | $5.3M+9.0% | $4.9M+39.1% | $3.5M-0.5% | $3.5M-31.8% | $5.2M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.0M-27.5% | $24.8M+53.9% | $16.1M-8.8% | $17.7M+36.1% | $13.0M+21.8% | $10.7M-59.6% | $26.4M+14.2% | $23.1M |
| Current Liabilities | $12.6M-36.2% | $19.7M+79.6% | $11.0M-8.8% | $12.0M+9.0% | $11.0M+19.0% | $9.3M-34.0% | $14.0M-22.4% | $18.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.6M+44.7% | -$4.7M-1033.6% | $500K-88.7% | $4.4M-19.8% | $5.5M-49.3% | $10.9M+301.5% | -$5.4M-213.0% | $4.8M |
| Retained Earnings | -$133.6M-5.2% | -$126.9M-4.4% | -$121.6M-3.6% | -$117.4M-1.2% | -$116.0M-5.1% | -$110.3M-0.2% | -$110.1M-10.5% | -$99.7M |
BFRI Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M-25.6% | -$3.0M+26.0% | -$4.1M-304.8% | -$1.0M+15.8% | -$1.2M+74.4% | -$4.7M-42.0% | -$3.3M+62.5% | -$8.9M |
| Capital Expenditures | -$1K-200.0% | $1K-66.7% | $3K+200.0% | $1K | $0+100.0% | -$48K-184.2% | $57K+733.3% | -$9K |
| Free Cash Flow | -$3.8M-25.5% | -$3.0M+26.1% | -$4.1M-304.7% | -$1.0M+15.7% | -$1.2M+74.7% | -$4.8M-41.0% | -$3.4M+61.9% | -$8.9M |
| Investing Cash Flow | $1K+200.0% | -$1K+66.7% | -$3K-200.0% | -$1K | $0 | N/A | N/A | $73K |
| Financing Cash Flow | $0 | N/A | N/A | $4.0M+1459.1% | -$298K-105.6% | $5.3M-8.9% | $5.8M-13.6% | $6.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BFRI Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -89.8%-33.6pp | -56.3%-3.3pp | -52.9%-39.3pp | -13.6%+41.4pp | -55.0%+9.7pp | -64.7%+4.4pp | -69.1%-32.6pp | -36.5% |
| Net Margin | -95.2%-36.2pp | -59.0%-10.0pp | -48.9%-37.8pp | -11.1%+51.8pp | -62.9%-59.6pp | -3.3%+128.6pp | -131.9%-165.2pp | 33.3% |
| Return on Equity | N/A | N/A | -840.6%-809.1pp | -31.5%+71.0pp | -102.5%-100.1pp | -2.4% | N/A | 73.6% |
| Return on Assets | -43.1%-16.7pp | -26.4%-1.1pp | -25.3%-19.0pp | -6.3%+24.3pp | -30.6%-29.4pp | -1.2%+41.3pp | -42.5%-55.1pp | 12.6% |
| Current Ratio | 1.15+0.2 | 0.96-0.4 | 1.40-0.3 | 1.72+0.2 | 1.53-0.4 | 1.89+0.4 | 1.44+0.2 | 1.28 |
| Debt-to-Equity | -6.97-1.7 | -5.31-37.6 | 32.24+28.3 | 3.99+1.6 | 2.35+1.4 | 0.98+5.9 | -4.88-9.7 | 4.83 |
| FCF Margin | -54.7%-21.0pp | -33.7%+14.2pp | -48.0%-39.9pp | -8.1%+5.3pp | -13.4%+47.4pp | -60.8%-18.1pp | -42.8%+41.0pp | -83.8% |
Similar Companies
Frequently Asked Questions
What is Biofrontera Inc's annual revenue?
Biofrontera Inc (BFRI) reported $41.7M in total revenue for fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biofrontera Inc's revenue growing?
Biofrontera Inc (BFRI) revenue grew by 11.7% year-over-year, from $37.3M to $41.7M in fiscal year 2025.
Is Biofrontera Inc profitable?
No, Biofrontera Inc (BFRI) reported a net income of -$10.5M in fiscal year 2025, with a net profit margin of -25.3%.
What is Biofrontera Inc's EBITDA?
Biofrontera Inc (BFRI) had EBITDA of -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biofrontera Inc's gross margin?
Biofrontera Inc (BFRI) had a gross margin of 75.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biofrontera Inc's operating margin?
Biofrontera Inc (BFRI) had an operating margin of -27.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biofrontera Inc's net profit margin?
Biofrontera Inc (BFRI) had a net profit margin of -25.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biofrontera Inc's return on equity (ROE)?
Biofrontera Inc (BFRI) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biofrontera Inc's free cash flow?
Biofrontera Inc (BFRI) generated -$13.4M in free cash flow during fiscal year 2025. This represents a -30.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biofrontera Inc's operating cash flow?
Biofrontera Inc (BFRI) generated -$13.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biofrontera Inc's total assets?
Biofrontera Inc (BFRI) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biofrontera Inc's capital expenditures?
Biofrontera Inc (BFRI) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biofrontera Inc spend on research and development?
Biofrontera Inc (BFRI) invested $3.7M in research and development during fiscal year 2025.
What is Biofrontera Inc's current ratio?
Biofrontera Inc (BFRI) had a current ratio of 1.52 as of fiscal year 2025, which is generally considered healthy.
What is Biofrontera Inc's debt-to-equity ratio?
Biofrontera Inc (BFRI) had a debt-to-equity ratio of 1.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biofrontera Inc's return on assets (ROA)?
Biofrontera Inc (BFRI) had a return on assets of -36.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biofrontera Inc's cash runway?
Based on fiscal year 2025 data, Biofrontera Inc (BFRI) had $6.4M in cash against an annual operating cash burn of $13.4M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biofrontera Inc's Piotroski F-Score?
Biofrontera Inc (BFRI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biofrontera Inc's earnings high quality?
Biofrontera Inc (BFRI) has an earnings quality ratio of 1.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biofrontera Inc cover its interest payments?
Biofrontera Inc (BFRI) has an interest coverage ratio of -28.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biofrontera Inc?
Biofrontera Inc (BFRI) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.